Company: CSDX
Filing Date: 2025-10-09
Form Type: 10-Q
Source: 0001214659-25-014817
Chunk: 0

Company: CS DIAGNOSTICS CORP.
Filing Date: 2025-10-09
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
 from operating activities                                                                                                                        
  Net profit/ (loss)                                                                                                    32,264                         4,349  
  Adjustment to reconcile net loss to net cash used in operating activities                                                                                   
  Changes in assets and liabilities                                                                                                                           
  Other Receivables                                                                                                    (31,181                          8564  
  Account payables                                                                                                      (1,428                          (613  
  Net cash used in operating activities                                          $                                        (345      $                 12,300  
  Cash flows from investing activities                                                                                                                        
  Intangible Asset                                                                                                                              (499,444,401  
  Net cash provided by Investing activities                                                                                         $           (499,444,401  
  Cash flows from financing activities                                                                                                                        
  Additional Capital Paid Up                                                                                                                     499,444,401  
  Series C Shares                                                                                                           40                             -  
  Net cash provided by financing activities                                      $                                          40      $         499,444,401.00  
  Net increase /(decrease) in cash                                                                                        (305                        12,300  
  Cash beginning of period                                                                                                 501                         8,767  
  Cash end of period                                                             $                                         196      $                 21,067  

The accompanying notes are an integral part of these financial statements.

   7  

CS Diagnostics, Corp.

Notes to the Financial Statements

June 30, 2025, and December 31, 2024

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

CS
Diagnostics Corp., (the " Company") a Wyoming Corporation in the United State, CS Diagnostics
Corp., is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers
international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA
regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities,
experts and experienced users as well as with our users, as well as with our own R& D team, in order to always offer the most innovative
products in medical technology.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America (“ U. S. GAAP”).

Use of Estimates

The preparation of financial statements in conformity
with generally accepted accounting principles requires management to